Toyama Chemical out-licenses RA drug to Turkey’s TR-Pharm
Fujifilm Group company Toyama Chemical has signed a licensing agreement with Turkish drugmaker TR-Pharm concerning Toyama’s rheumatoid arthritis drug iguratimod (T-614).
Iguratimod is a drug for treating rheumatoid arthritis jointly developed with Eisai (TYO: 4523). It was approved for manufacturing and marketing in Japan in June 2012 (The Pharma Letter July 3), and launched in the domestic market in September of the same year, under the trade names Kolbet and Careram.
The new licensing partner TR-Pharm is an affiliate of R-Pharm, a leading Russian drugmaker. TR-Pharm has been established as a development and manufacturing base for Turkey, Middle East and North Africa. TR-Pharm has over 10 agents in the development pipeline, focusing on the fields of oncology, virology and inflammatory diseases for business expansion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze